CYTOKINETICS, INCORPORATED Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
CYTOKINETICS, INCORPORATED (CYTK) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $1.46M, a 67.57% decline from fiscal 2024.
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $4.51M, a 1116.71% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $371.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $1.46M 10-K · filed 2026-02-26 |
| 2024-12-31 | $4.51M 10-K · filed 2026-02-26 |
| 2023-12-31 | $371.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |